Thalidomide: (re) discovery of a not very dear old molecule

Bressoud, Aéric.; Schwab, Béatrice.Zimmerli.

Revue Medicale de la Suisse Romande 123(4): 238-240

2003


ISSN/ISBN: 0035-3655
PMID: 15088555
Document Number: 553753
The angiogenesis is an early event in tumorigenesis. Angiogenesis inhibitors have been developed and are now studied in clinical trials. Angiogenesis research has induced a renewal of thalidomide. Thalidomide inhibits tumoral angiogenesis, allowing a good palliative treatment for hematological malignancies, especially for multiple myeloma and myelodysplastic syndromes.

Document emailed within 1 workday
Secure & encrypted payments